Cite
HARVARD Citation
Fuhr, R. et al. (2022). Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis. Mycoses. 65 (6), pp. 661-669. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Fuhr, R. et al. (2022). Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis. Mycoses. 65 (6), pp. 661-669. [Online].